tiprankstipranks
Pelthos Therapeutics (PTHS)
:PTHS
US Market
PTHS
Pelthos Therapeutics
RESEARCH TOOLSreports

Pelthos Therapeutics (PTHS) Stock Forecast & Price Target

71 Followers
See the Price Targets and Ratings of:

PTHS Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Pelthos
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PTHS Stock 12 Month Forecast

Average Price Target

$57.14
▲(149.52% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Pelthos Therapeutics in the last 3 months. The average price target is $57.14 with a high forecast of $75.00 and a low forecast of $48.00. The average price target represents a 149.52% change from the last price of $22.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,25.430769230769233,29.56153846153846,33.69230769230769,37.823076923076925,41.95384615384616,46.08461538461539,50.21538461538462,54.346153846153854,58.476923076923086,62.60769230769232,66.73846153846155,70.86923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,24.056923076923077,26.813846153846157,29.570769230769233,32.32769230769231,35.08461538461539,37.84153846153846,40.59846153846154,43.35538461538462,46.112307692307695,48.86923076923077,51.626153846153855,54.38307692307693,{"y":57.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,23.353846153846156,25.407692307692308,27.46153846153846,29.515384615384615,31.56923076923077,33.62307692307692,35.676923076923075,37.730769230769226,39.78461538461538,41.83846153846154,43.892307692307696,45.94615384615385,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.7,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.7,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.7,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.7,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$57.14Lowest Price Target$48.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Alliance Global Partners Analyst forecast on PTHS
James Molloy
Alliance Global Partners
Alliance Global Partners
$75
Buy
227.51%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Cantor Fitzgerald Analyst forecast on PTHS
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$50
Buy
118.34%
Upside
Initiated
04/01/26
Pelthos Therapeutics initiated with an Overweight at Cantor FitzgeraldPelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Lake Street Analyst forecast on PTHS
Thomas Flaten
Lake Street
Lake Street
$50
Buy
118.34%
Upside
Reiterated
03/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS) and Sanofi (Other OTC: SNYNF)
Oppenheimer Analyst forecast on PTHS
Jeff Jones
Oppenheimer
Oppenheimer
$60→$62
Buy
170.74%
Upside
Reiterated
03/20/26
Pelthos Therapeutics price target raised to $62 from $60 at OppenheimerPelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
Piper Sandler Analyst forecast on PTHS
David Amsellem
Piper Sandler
Piper Sandler
$48
Buy
109.61%
Upside
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH) and Pelthos Therapeutics (NYSE MKT: PTHS)
H.C. Wainwright Analyst forecast on PTHS
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$60
Buy
162.01%
Upside
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Ibio (NASDAQ: IBIO) and Pelthos Therapeutics (NYSE MKT: PTHS)
Roth MKM Analyst forecast on PTHS
Jonathan Aschoff
Roth MKM
Roth MKM
$55
Buy
140.17%
Upside
Reiterated
03/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pelthos Therapeutics (NYSE MKT: PTHS) and Viatris (NASDAQ: VTRS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Alliance Global Partners Analyst forecast on PTHS
James Molloy
Alliance Global Partners
Alliance Global Partners
$75
Buy
227.51%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Cantor Fitzgerald Analyst forecast on PTHS
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$50
Buy
118.34%
Upside
Initiated
04/01/26
Pelthos Therapeutics initiated with an Overweight at Cantor FitzgeraldPelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Lake Street Analyst forecast on PTHS
Thomas Flaten
Lake Street
Lake Street
$50
Buy
118.34%
Upside
Reiterated
03/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS) and Sanofi (Other OTC: SNYNF)
Oppenheimer Analyst forecast on PTHS
Jeff Jones
Oppenheimer
Oppenheimer
$60→$62
Buy
170.74%
Upside
Reiterated
03/20/26
Pelthos Therapeutics price target raised to $62 from $60 at OppenheimerPelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
Piper Sandler Analyst forecast on PTHS
David Amsellem
Piper Sandler
Piper Sandler
$48
Buy
109.61%
Upside
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH) and Pelthos Therapeutics (NYSE MKT: PTHS)
H.C. Wainwright Analyst forecast on PTHS
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$60
Buy
162.01%
Upside
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Ibio (NASDAQ: IBIO) and Pelthos Therapeutics (NYSE MKT: PTHS)
Roth MKM Analyst forecast on PTHS
Jonathan Aschoff
Roth MKM
Roth MKM
$55
Buy
140.17%
Upside
Reiterated
03/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pelthos Therapeutics (NYSE MKT: PTHS) and Viatris (NASDAQ: VTRS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pelthos Therapeutics

3 Months
xxx
Success Rate
1/3 ratings generated profit
33%
Average Return
-5.77%
reiterated a xxx
 rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -5.77% per trade.
1 Year
Brandon FolkesH.C. Wainwright
Success Rate
1/3 ratings generated profit
33%
Average Return
-4.07%
reiterated a buy rating 21 days ago
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.07% per trade.
2 Years
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
+7.20%
reiterated a xxx
 rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +7.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTHS Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
15
22
23
27
21
Buy
2
2
0
0
0
Hold
0
12
12
13
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
36
35
40
26
In the current month, PTHS has received 21 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PTHS average Analyst price target in the past 3 months is 57.14.
Each month's total comprises the sum of three months' worth of ratings.

PTHS Financial Forecast

PTHS Earnings Forecast

Next quarter’s earnings estimate for PTHS is -$3.70 with a range of -$5.15 to -$1.55. The previous quarter’s EPS was -$5.30. PTHS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year PTHS has its overall industry.
Next quarter’s earnings estimate for PTHS is -$3.70 with a range of -$5.15 to -$1.55. The previous quarter’s EPS was -$5.30. PTHS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year PTHS has its overall industry.

PTHS Sales Forecast

Next quarter’s sales forecast for PTHS is $9.09M with a range of $8.81M to $9.40M. The previous quarter’s sales results were $7.41M. PTHS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year PTHS has its overall industry.
Next quarter’s sales forecast for PTHS is $9.09M with a range of $8.81M to $9.40M. The previous quarter’s sales results were $7.41M. PTHS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year PTHS has its overall industry.

PTHS Stock Forecast FAQ

What is PTHS’s average 12-month price target, according to analysts?
Based on analyst ratings, Pelthos Therapeutics’s 12-month average price target is 57.14.
    What is PTHS’s upside potential, based on the analysts’ average price target?
    Pelthos Therapeutics has 149.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PTHS a Buy, Sell or Hold?
          Pelthos Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Pelthos Therapeutics’s price target?
            The average price target for Pelthos Therapeutics is 57.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $48.00. The average price target represents 149.52% Increase from the current price of $22.9.
              What do analysts say about Pelthos Therapeutics?
              Pelthos Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of PTHS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.